David S. Schade
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David S. Schade has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
R. Philip Eaton
Professor of Medicine, Internal Medicine; Division of Endocrinology; University of New Mexico Health Sciences, Albuquerque, NM
21 shared publicationsAllen Adolphe
Professor of Medicine, Internal Medicine; Division of General Internal Medicine; University of New Mexico Health Sciences Center, Albuquerque, NM
8 shared publications- R. Philip Eaton
Department of Internal Medicine, Division of Endocrinology, University of New Mexico Health Sciences Center, Albuquerque
6 shared publications Barry Ramo
Medical Director, New Heart Fitness and Health, Albuquerque, New Mexico
4 shared publicationsLynda Shey
University of New Mexico Hospital, Diabetes Comprehensive Care Center, Albuquerque, New Mexico
4 shared publicationsMark R. Burge
Division of Endocrinology, DoIM, University of New Mexico School of Medicine, Albuquerque, New Mexico 87131
4 shared publications
Latest Publications
- 22 April 2026
- Published by Elsevier in Endocrine Practice
- Vol. 32 (9) , 1419-1421
PREVENT Equations Versus Polled Cohort Equations Versus Multi-Ethnic Study of Atherosclerosis Equations—How Should the Physician Choose?
- 22 April 2026
- Published by Elsevier in Endocrine Practice
- Vol. 32 (9) , 1419-1421
PREVENT Equations Versus Polled Cohort Equations Versus Multi-Ethnic Study of Atherosclerosis Equations—How Should the Physician Choose?
- 19 March 2026
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (11) , 1409-1412
The scientific justification for abandoning risk factor-based guidelines for the prevention of atherosclerotic cardiovascular disease
- 19 March 2026
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (11) , 1409-1412
The scientific justification for abandoning risk factor-based guidelines for the prevention of atherosclerotic cardiovascular disease
- 10 March 2026
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (7) , 843-847
Ten reasons to treat all individuals with a positive coronary artery calcium score
- 10 March 2026
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (7) , 843-847
Ten reasons to treat all individuals with a positive coronary artery calcium score
- 17 November 2025
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (4) , 384-387
Cardiovascular disease risk assessment from circulating lipid particles–A new challenge for physicians
- 17 November 2025
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (4) , 384-387
Cardiovascular disease risk assessment from circulating lipid particles–A new challenge for physicians
- 16 October 2025
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (3) , 276-282
A new paradigm to reduce cardiovascular disease based on the pathogenesis of atherosclerosis
- 16 October 2025
- Published by Elsevier in The American Journal of Medicine
- Vol. 139 (3) , 276-282
A new paradigm to reduce cardiovascular disease based on the pathogenesis of atherosclerosis
- 23 September 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (11) , 1960-1970
Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort
OBJECTIVE: To describe the prevalence and incidence of electrocardiogram (ECG) abnormalities and ECG-derived cardiovascular autonomic neuropathy (CAN) in the GRADE cohort of adults with type 2 diabetes (T2D) <10 years. RESEARCH DESIGN AND METHODS: Individuals with T2D taking metformin alone were randomly assigned to add insulin glargine, glimepiride, liraglutide, or sitagliptin. Resting ECGs were completed at the baseline, 2-year, and 4-year study visits and analyzed for minor and major abnormalities and CAN assessed with heart rate variability (HRV) in 4,769 participants. Incidence of new major, minor, and any ECG abnormalities and CAN by treatment group was analyzed using logistic repeated-measures models at years 2 and 4 adjusted for baseline risk factors. RESULTS: At baseline, participants were a mean age of 57.2 ± 10.0 years, 36.3% were women, mean diabetes duration was 4.3 ± 2.8 years, and mean HbA1c was 7.5 ± 0.5%. Participants with ECG abnormalities at baseline (57.1%) and ECG-derived CAN (52.8%) were older and had more severe cardiovascular risk factors. The incidence of minor and major ECG abnormalities was similar among all treatment groups. However, at year 4, major ECG abnormalities were fewer in the liraglutide versus nonliraglutide groups (9% vs. 13%; P = 0.03). The incidence of CAN did not differ between the liraglutide and nonliraglutide groups across visits (P = 0.42); however, one measure of HRV (SD of normal-to-normal R-R intervals) was higher at year 2 in the liraglutide versus nonliraglutide groups (P = 0.02). CONCLUSIONS: ECG abnormalities, including those reflecting CAN, are common in individuals with T2D <10 years and more so in those with certain cardiovascular risk factors. The development of major ECG abnormalities may be lower with liraglutide.
- 23 September 2025
- Published by American Diabetes Association in Diabetes Care
- Vol. 48 (11) , 1960-1970
Differences in Prevalence and Incidence of Electrocardiogram Abnormalities and Cardiovascular Autonomic Neuropathy Among Randomized Glucose-Lowering Treatments in Early Type 2 Diabetes: The Glycemia Reduction Approaches in Diabetes (GRADE) Cohort
OBJECTIVE: To describe the prevalence and incidence of electrocardiogram (ECG) abnormalities and ECG-derived cardiovascular autonomic neuropathy (CAN) in the GRADE cohort of adults with type 2 diabetes (T2D) <10 years. RESEARCH DESIGN AND METHODS: Individuals with T2D taking metformin alone were randomly assigned to add insulin glargine, glimepiride, liraglutide, or sitagliptin. Resting ECGs were completed at the baseline, 2-year, and 4-year study visits and analyzed for minor and major abnormalities and CAN assessed with heart rate variability (HRV) in 4,769 participants. Incidence of new major, minor, and any ECG abnormalities and CAN by treatment group was analyzed using logistic repeated-measures models at years 2 and 4 adjusted for baseline risk factors. RESULTS: At baseline, participants were a mean age of 57.2 ± 10.0 years, 36.3% were women, mean diabetes duration was 4.3 ± 2.8 years, and mean HbA1c was 7.5 ± 0.5%. Participants with ECG abnormalities at baseline (57.1%) and ECG-derived CAN (52.8%) were older and had more severe cardiovascular risk factors. The incidence of minor and major ECG abnormalities was similar among all treatment groups. However, at year 4, major ECG abnormalities were fewer in the liraglutide versus nonliraglutide groups (9% vs. 13%; P = 0.03). The incidence of CAN did not differ between the liraglutide and nonliraglutide groups across visits (P = 0.42); however, one measure of HRV (SD of normal-to-normal R-R intervals) was higher at year 2 in the liraglutide versus nonliraglutide groups (P = 0.02). CONCLUSIONS: ECG abnormalities, including those reflecting CAN, are common in individuals with T2D <10 years and more so in those with certain cardiovascular risk factors. The development of major ECG abnormalities may be lower with liraglutide.
- 6 June 2025
- Published by Elsevier in The American Journal of Medicine
- Vol. 138 (11) , 1482-1484
Elevated Lipoprotein(a): A Treatment Challenge and a Practical Solution
- 6 June 2025
- Published by Elsevier in The American Journal of Medicine
- Vol. 138 (11) , 1482-1484
Elevated Lipoprotein(a): A Treatment Challenge and a Practical Solution
- Open Access
- 17 March 2025
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 3 (4) , luaf050
An Unusual Case of Factitious Disorder Manifesting as Hypercalcemia Mediated by Exogenous Calcitriol
Excessive 1, 25-dihydroxy vitamin D (calcitriol) is a pathophysiological cause of hypercalcemia. This form of hypercalcemia is seen in autoimmune conditions, fungal infections, lymphoma, and rare genetic diseases. A factious disorder manifesting as intentional ingestion of calcitriol leading to hypercalcemia has not been previously reported. We report a case of a female in the fourth decade with recurrent episodes of hypercalcemia seen at multiple clinics across the United States over a period of 20 years. Several extensive medical workups were unable to identify a specific cause of her non-PTH mediated hypercalcemia. We used a novel approach to determine that her hypercalcemia was secondary to exogenous calcitriol administration. When the patient realized that the etiology had been identified, she refused all further contact with the physician. It is not uncommon for patients with a factitious disorder to deny self-inflicting behavior or to seek care somewhere else. Ingestion of calcitriol should be considered when the etiology of recurrent hypercalcemia cannot be identified by traditional medical testing.
- 17 March 2025
- Published by The Endocrine Society in JCEM Case Reports
- Vol. 3 (4) , luaf050
Open AccessAn Unusual Case of Factitious Disorder Manifesting as Hypercalcemia Mediated by Exogenous Calcitriol
Excessive 1, 25-dihydroxy vitamin D (calcitriol) is a pathophysiological cause of hypercalcemia. This form of hypercalcemia is seen in autoimmune conditions, fungal infections, lymphoma, and rare genetic diseases. A factious disorder manifesting as intentional ingestion of calcitriol leading to hypercalcemia has not been previously reported. We report a case of a female in the fourth decade with recurrent episodes of hypercalcemia seen at multiple clinics across the United States over a period of 20 years. Several extensive medical workups were unable to identify a specific cause of her non-PTH mediated hypercalcemia. We used a novel approach to determine that her hypercalcemia was secondary to exogenous calcitriol administration. When the patient realized that the etiology had been identified, she refused all further contact with the physician. It is not uncommon for patients with a factitious disorder to deny self-inflicting behavior or to seek care somewhere else. Ingestion of calcitriol should be considered when the etiology of recurrent hypercalcemia cannot be identified by traditional medical testing.
- 29 January 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (1) , e261106
Minimal methimazole exposure-induced fatal pancytopenia
This case highlights that refractory pancytopenia leading to death can occur with methimazole treatment even at a very low cumulative dose and after a very short duration of exposure. In addition, the standard treatments to correct the pancytopenia may not be effective and a bone marrow transplant may be required. Current American Thyroid Association guidelines do not recommend routine monitoring of the complete blood count in patients receiving thionamides because of the rapidity of the onset of agranulocytosis and the lack of positive evidence that such monitoring would be useful. Patient education concerning the clinical adverse effects of pancytopenia should be stressed before drug initiation. Patients should discontinue thionamides immediately and seek medical treatment if they develop anaemia, fever, pharyngitis, severe infection or easy bruising. Physicians need to be aware that pancytopenia from methimazole is not dose-related and be alert to any patient signs or symptoms of infection. Subspecialty consultation will be required.
- 29 January 2025
- Published by BMJ in BMJ Case Reports
- Vol. 18 (1) , e261106
Minimal methimazole exposure-induced fatal pancytopenia
This case highlights that refractory pancytopenia leading to death can occur with methimazole treatment even at a very low cumulative dose and after a very short duration of exposure. In addition, the standard treatments to correct the pancytopenia may not be effective and a bone marrow transplant may be required. Current American Thyroid Association guidelines do not recommend routine monitoring of the complete blood count in patients receiving thionamides because of the rapidity of the onset of agranulocytosis and the lack of positive evidence that such monitoring would be useful. Patient education concerning the clinical adverse effects of pancytopenia should be stressed before drug initiation. Patients should discontinue thionamides immediately and seek medical treatment if they develop anaemia, fever, pharyngitis, severe infection or easy bruising. Physicians need to be aware that pancytopenia from methimazole is not dose-related and be alert to any patient signs or symptoms of infection. Subspecialty consultation will be required.
- 26 March 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (13) , 993-1003
Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)
BACKGROUND: Cardiovascular disease is a major cause of morbidity and mortality in patients with type 2 diabetes. The effects of glucose-lowering medications on cardiovascular outcomes in individuals with type 2 diabetes and low cardiovascular risk are unclear. We investigated cardiovascular outcomes by treatment group in participants randomly assigned to insulin glargine, glimepiride, liraglutide, or sitagliptin, added to baseline metformin, in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study). METHODS: A total of 5047 participants with a mean±SD age of 57.2±10.0 years, type 2 diabetes duration of 4.0±2.7 years, and low baseline prevalence of cardiovascular disease (myocardial infarction, 5.1%; cerebrovascular accident, 2.0%) were followed for a median of 5 years. Prespecified outcomes included between-group time-to-first event analyses of MACE-3 (composite of major adverse cardiovascular events: cardiovascular death, myocardial infarction, and stroke), MACE-4 (MACE-3+unstable angina requiring hospitalization or revascularization), MACE-5 (MACE-4+coronary revascularization), MACE-6 (MACE-5+hospitalization for heart failure), and the individual components. MACE outcomes and hospitalization for heart failure in the liraglutide-treated group were compared with the other groups combined using Cox proportional hazards models. MACE-6 was also analyzed as recurrent events using a proportional rate model to compare all treatment groups. RESULTS: We observed no statistically significant differences in the cumulative incidence of first MACE-3, MACE-4, MACE-5, or MACE-6, or their individual components, by randomized treatment group. However, when compared with the other treatment groups combined, the liraglutide-treated group had a significantly lower risk of MACE-5 (adjusted hazard ratio, 0.70 [95% CI, 0.54–0.91]; P =0.021), MACE-6 (adjusted hazard ratio, 0.70 [95% CI, 0.55–0.90]; P =0.021), and hospitalization for heart failure (adjusted hazard ratio, 0.49 [95% CI, 0.28–0.86]; P =0.022). Compared with the liraglutide group, significantly higher rates of recurrent MACE-6 events occurred in the groups treated with glimepiride (rate ratio, 1.61 [95% CI, 1.13–2.29]) or sitagliptin (rate ratio 1.75; [95% CI, 1.24–2.48]). CONCLUSIONS: This comparative effectiveness study of a contemporary cohort of adults with type 2 diabetes, largely without established cardiovascular disease, suggests that liraglutide treatment may reduce the risk of cardiovascular events in patients at relatively low risk compared with other commonly used glucose-lowering medications. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01794143.
- 26 March 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 149 (13) , 993-1003
Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)
BACKGROUND: Cardiovascular disease is a major cause of morbidity and mortality in patients with type 2 diabetes. The effects of glucose-lowering medications on cardiovascular outcomes in individuals with type 2 diabetes and low cardiovascular risk are unclear. We investigated cardiovascular outcomes by treatment group in participants randomly assigned to insulin glargine, glimepiride, liraglutide, or sitagliptin, added to baseline metformin, in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study). METHODS: A total of 5047 participants with a mean±SD age of 57.2±10.0 years, type 2 diabetes duration of 4.0±2.7 years, and low baseline prevalence of cardiovascular disease (myocardial infarction, 5.1%; cerebrovascular accident, 2.0%) were followed for a median of 5 years. Prespecified outcomes included between-group time-to-first event analyses of MACE-3 (composite of major adverse cardiovascular events: cardiovascular death, myocardial infarction, and stroke), MACE-4 (MACE-3+unstable angina requiring hospitalization or revascularization), MACE-5 (MACE-4+coronary revascularization), MACE-6 (MACE-5+hospitalization for heart failure), and the individual components. MACE outcomes and hospitalization for heart failure in the liraglutide-treated group were compared with the other groups combined using Cox proportional hazards models. MACE-6 was also analyzed as recurrent events using a proportional rate model to compare all treatment groups. RESULTS: We observed no statistically significant differences in the cumulative incidence of first MACE-3, MACE-4, MACE-5, or MACE-6, or their individual components, by randomized treatment group. However, when compared with the other treatment groups combined, the liraglutide-treated group had a significantly lower risk of MACE-5 (adjusted hazard ratio, 0.70 [95% CI, 0.54–0.91]; P =0.021), MACE-6 (adjusted hazard ratio, 0.70 [95% CI, 0.55–0.90]; P =0.021), and hospitalization for heart failure (adjusted hazard ratio, 0.49 [95% CI, 0.28–0.86]; P =0.022). Compared with the liraglutide group, significantly higher rates of recurrent MACE-6 events occurred in the groups treated with glimepiride (rate ratio, 1.61 [95% CI, 1.13–2.29]) or sitagliptin (rate ratio 1.75; [95% CI, 1.24–2.48]). CONCLUSIONS: This comparative effectiveness study of a contemporary cohort of adults with type 2 diabetes, largely without established cardiovascular disease, suggests that liraglutide treatment may reduce the risk of cardiovascular events in patients at relatively low risk compared with other commonly used glucose-lowering medications. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01794143.